Robak, T. (Tadeusz)

Filtering

20191

Settings

Author search.filters.isAuthorOfPublication.c042d43a-9ca6-4ecc-b841-b5ee4f2e705e

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
    (Springer Science and Business Media LLC, 2019) Oberic, L. (Lucie); Patel, P (Priti); Yin, M. (Ming); Dupuis, J. (Jehan); Shah, B. (Bijal); Robak, T. (Tadeusz); Le-Gouill, S. (Steven); Damaj, G. (Gandhi); Raquel; Jacobsen, E. (Eric); Jain, P. (Preetesh); Panizo, C. (Carlos); Lamy, T. (Thierry); Frigault, M.M. (Melanie M.); Rule, S. (Simon); Dlugosz-Danecka, M. (Monika); Davies, A. (Andrew); Smith, S.D. (Stephen D.); Doorduijn, J.K. (Jeanette K.); Kate, A.P. (Arnon P.); Morschhauser, F. (Franck); Casasnovas, R. O. (René Olivier); Goy, A. (Andre); Wang, M. (Michael); Eek, R. (Richard); Zinzani, P.L. (P. L.); Nguyen, D. (Dorothy)
    Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10−6 ) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018.